Navigation Links
Sublingual immunotherapy shows promise as treatment for peanut allergy
Date:1/7/2013

CHAPEL HILL, N.C. Peanuts are one of the most common triggers of severe food-induced allergic reactions, which can be fatal, and the prevalence of peanut allergy is increasing. However, there is currently no clinical treatment available for peanut allergy other than strict dietary elimination and, in cases of accidental ingestion, injections of epinephrine.

But a new multicenter clinical trial shows promise for sublingual immunotherapy (SLIT), a treatment in which patients are given daily doses, in gradually increasing amounts, of a liquid containing peanut powder. The patients first hold the liquid under the tongue for 2 minutes and then swallow it.

The two lead authors of the study, published in the January 2013 issue of the Journal of Allergy and Clinical Immunology, are David M. Fleischer, MD, of National Jewish Health in Denver, Colo., and Wesley Burks, MD, Curnen Distinguished Professor and Chair of the Department of Pediatrics in the University of North Carolina School of Medicine.

"These results are encouraging," Burks said. "The immune response was stronger than we thought it might be, and the side effects of this treatment were relatively small. However, the magnitude of the therapeutic effect was somewhat less than we had anticipated. That's an issue we plan to address in future studies."

In the study, 40 people with peanut allergy, ages 12 to 37 years, were randomized to receive daily peanut or placebo SLIT. All were given a baseline oral food challenge of up to 2 grams of peanut powder to test how much peanut powder they could consume without symptoms.

After 44 weeks, all were given a second oral food challenge. Those who were able to consume either 5 grams, or at least 10-fold more peanut powder than their baseline amount, were considered to be responders (i.e., desensitized to peanut). At 44 weeks, 70 percent of those who received peanut SLIT were responders, compared to 15 percent of those receiving placebo. Among the peanut-SLIT responders, the median amount of peanut powder they could successfully consume increased from 3.5 to 496 milligrams. After 68 weeks, that amount increased significantly, to 996 milligrams.

Of 10,855 peanut doses given through week 44 of the study, 63.1 percent were symptom-free. When oral/pharyngeal symptoms were excluded from the analysis, 95.2 percent of doses were symptom-free.

The study concluded that peanut SLIT safely induced desensitization in a majority of participants compared to placebo, and that longer duration of therapy led to significant increases in the amount of peanut powder people could safely consume.

However, Burks cautions, this is not a treatment that people should try on their own. For now it's a treatment that should only be given by medical professionals in a carefully monitored clinical trial, he said.


'/>"/>

Contact: Tom Hughes
tahughes@unch.unc.edu
919-966-6047
University of North Carolina Health Care
Source:Eurekalert  

Related medicine news :

1. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
2. Antibodies reverse type 1 diabetes in new immunotherapy study
3. Immunotherapy for elderly cancer patients finds new promise in drug combination
4. Peanut therapy shows promise in treating peanut allergy
5. Research shows that a prolonged fertility window can cause recurrent miscarriage
6. PET/CT shows clear advantages over conventional staging for breast cancer patients
7. A Feinstein Institute for Medical Research Study Shows Early Cognitive Problems among Those Who Eventually Get Alzheimer's
8. Mount Sinai survey shows that nearly 1 in 3 children with food allergies experience bullying
9. HistoWiki.com's Clint Evans Announces Kindle Book Giveaway Which Shows the Missing Links from Michelle Obama's "Let's Move" Weight Loss Program
10. Study shows heart calcium scan predictive of diabetes-related death from cardiovascular disease
11. Temple researcher shows diabetes, blood pressure link to colon cancer recurrence, survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sublingual immunotherapy shows promise as treatment for peanut allergy
(Date:1/16/2017)... Grants Pass, OR (PRWEB) , ... January 16, ... ... Kent Heckenlively, author, editor, attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, ... and attorney Kent Heckenlively to her nationally syndicated radio program, The Sharon Kleyne ...
(Date:1/16/2017)... ... 16, 2017 , ... In 1985, the International Association of ... to an international multidisciplinary group of healthcare treatment providers and helping professions who ... its mission at the grassroots level, iaedp launched MemberSHARE, an online peer community ...
(Date:1/16/2017)... San Francisco, CA (PRWEB) , ... January 16, 2017 , ... ... the incorporation of iTero Element, the latest in 3-D scanning device which is capable ... some of the latest advances in dentistry, such as CAD CAM restorations , ...
(Date:1/16/2017)... ... 2017 , ... NexTec Group has been selected as a member of the ... accomplishments in the field of midmarket financial software. , Members of the VAR Stars ... is not based on revenue and those firms chosen represent a wide range of ...
(Date:1/15/2017)... ... January 15, 2017 , ... Going ... a program that strives to better communities around the world by offering the ... also provides the opportunity for team members to become involved in a cause ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Potential, Competitive Strategies and Forecasts: 2017 - 2021" ... ... the 11 major NIPT test by the year end of 2021. ... the market and contains thoughtful insights, facts, historical data, and statistically ...
(Date:1/16/2017)... NEW YORK , Jan. 16, 2017 /PRNewswire/ ... global peripherally inserted central catheters market for the ... is to offer updates and information related to ... catheters market. This comprehensive market study demonstrates the ... current environment and future status of the global ...
(Date:1/16/2017)... Inc., a leading manufacturer and marketer of imaging and respiratory ... TM Single-Use video laryngoscopes. The new Spectrum blades ... TM technology, which actively optimizes image quality. ... ... Introducing another bright idea from GlideScope(R) Video Laryngoscopes: SPECTRUM. ...
Breaking Medicine Technology: